Welcome, Guest. Please login or register.
February 26, 2021, 04:14:09 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 55033
  • Total Topics: 4830
  • Online Today: 41
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 29
Total: 29

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Three-Drug Immunotherapy Combo Shrinks Liver Tumors  (Read 407 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Three-Drug Immunotherapy Combo Shrinks Liver Tumors
« on: June 24, 2020, 02:39:05 pm »
A triple combination of two immunotherapy drugs plus a targeted therapy led to better responses than a double regimen in people with advanced liver cancer, according to a study presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium last month in San Francisco. However, adding more drugs also increased side effects, and more research is needed to weigh the risks and benefits of this approach.

Over years or decades, chronic hepatitis B or C, heavy alcohol use, fatty liver disease and other causes can lead to the development of liver cirrhosis and hepatocellular carcinoma (HCC), the most common type of liver cancer. This cancer is often detected late and is difficult to treat. Although it generally does not respond well to chemotherapy, several new immunotherapies and targeted therapies have been approved for HCC in recent years.

Read more...
https://www.hepmag.com/article/threedrug-immunotherapy-combo-shrinks-liver-tumors

 


© 2021 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.